Sign up
Pharma Capital

Synairgen's chief hails exciting IPF data from LOXL2 inhibitor programme

Richard Marsden, chief executive at Synairgen (LON:SNG) discusses the further positive data from its LOXL2 inhibitor programme against the lung disease IPF.


View full SNG profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.